In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy

OncoImmunology

Volumn 4, Issue 9, 2015, Pages 1-11

  Gonzalez, Nela Klein ^a,b   Wennhold, Kerstin ^b   Balkow, Sandra ^c   Kondo, Eisei ^d   Bölck, Birgit ^e   Weber, Tanja ^b   Garciamarquez, Maria ^b   Grabbe, Stephan ^c   Bloch, Wilhelm ^e   von Bergwelt Baildon, Michael ^b   Shimabukuro Vornhagen, Alexander ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d OKAYAMA UNIVERSITY   (Japan)

^e GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Antigen presentation; Cancer immunotherapy; CD40 activated B cells; Cellular adjuvant; Migration

Indexed keywords

CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; TIME-LAPSE VIDEO MICROSCOPY;

EID: 84944453952     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1038684     Document Type: Article

References (44)

1. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003; 4:579-85; PMID:12730692; http://dx.doi.org/ 10.1038/ni928
2. Miller MJ, Safrina O, Parker I, Cahalan MD. Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med 2004; 200:847-56; PMID:15466619; http://dx.doi.org/ 10.1084/jem.20041236
3. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: dendritic cellbased interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi. org/10.4161/onci.21494
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/ 10.1056/NEJMoa1001294
5. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175
6. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I-and class II-binding peptides. Immunology 2008; 124:129-40; PMID:18067555; http://dx.doi.org/10.1111/j.1365-2567.2007.02749.x
7. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One 2011; 6:e24167; PMID:21904611; http://dx.doi.org/10.1371/journal. pone.0024167
8. CarpenterEL,MickR,Rüter J,VonderheideRH.Activation of humanBcells by the agonistCD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 2009; 7:93; PMID:19906293; http://dx.doi.org/10.1186/1479-5876-7-93
9. Von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY,Wucherpfennig KW, Nadler LM et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002; 99:3319-25; PMID:11964299; http://dx. doi.org/10.1182/blood.V99.9.3319
10. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, Rezvani K, Price DA, Hensel NF, Douek DC et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res 2005; 11:4495-503; PMID:15958635; http://dx.doi.org/ 10.1158/1078-0432.CCR-04-2363
11. Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo KU, Vonderheide RH. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 2008; 15:955-65; PMID:18337841; http://dx.doi.org/ 10.1038/gt.2008.22
12. Park MY, Kim HS, Woo SJ, Kim CH, Park JS, Sohn HJ, Kim HJ, Oh ST, Kim TG. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells. Eur J Immunol 2008; 38:2106-17; PMID:18624349; http://dx.doi. org/10.1002/eji.200737960
13. Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol 2009; 155:249-56; PMID:19040609; http://dx.doi. org/10.1111/j.1365-2249.2008.03820.x
14. Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Koc M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res 2012; 31:47; PMID:22592077; http://dx.doi.org/10.1186/1756-9966-31-47
15. Shimabukuro-Vornhagen A, Draube A, Liebig T, Popov A, Rothe A, von Bergwelt-Baildon M. The properties of human CD40-activated B cells as antigenpresenting cells are not affected by PGE2. Oncol Rep 2013; 29:1061-5; PMID:23292511; http://dx.doi.org/ 10.1038/gt.2008.22
16. Bishop GA, Hostager BS. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev 2003; 14:297-309; PMID:12787567; http://dx. doi.org/10.1016/S1359-6101(03)00024-8
17. Von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, Debey S, Draube A, Maecker B, Menezes I, Nadler LM et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 2006; 107:2786-9; PMID:16357329; http://dx.doi.org/10.1182/blood-2004-01-0113
18. Shimabukuro-Vornhagen A, Zoghi S, Liebig TM, Wennhold K, Chemitz J, Draube A, Kochanek M, Blaschke F, Pallasch C, Holtick U et al. Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity. J Immunol 2014; 193:5294-305; PMID:25311809; http://dx. doi.org/10.4049/jimmunol.1203436
19. Gunzer M, Weishaupt C, Hillmer A, Basoglu Y, Friedl P, Dittmar KE, Kolanus W, Varga G, Grabbe S. A spectrum of biophysical interaction modes between T cells and different antigen-presenting cells during priming in 3-D collagen and in vivo. Blood 2004; 104:2801-9; PMID:15256430; http://dx.doi.org/ 10.1182/blood-2004-03-1193
20. Liebig TM, Fiedler A, Zoghi S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon MS. Generation of human CD40-activated B cells. J Vis Exp [Internet] 2009; PMID:19838159; http://dx.doi.org/10.3791/1373.
21. Liebig TM, Fiedler A, Klein-Gonzalez N, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Murine model of CD40-activation of B cells. J Vis Exp [Internet] 2010 [cited 2010 Mar 30]; PMID:20208476; http://dx.doi.org/10.3791/1734.
22. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999; 286:2098-102; PMID:10617422; http://dx.doi.org/10.1126/science. 286.5447.2098
23. Stein JV, Nombela-Arrieta C. Chemokine control of lymphocyte trafficking: a general overview. Immunology 2005; 116:1-12; PMID:16108812; http://dx.doi. org/10.1111/j.1365-2567.2005.02183.x
24. Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, Förster R, Cyster JG. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002; 416:94-9; PMID:11882900; http://dx. doi.org/10.1038/416094a
25. Jeanbart L, Ballester M, de Titta A, Corthésy P, Romero P, Hubbell JA, Swartz MA. Enhancing efficacy of anticancer vaccines by targeted delivery to tumordraining lymph nodes. Cancer Immunol Res 2014; 2:436-47; PMID:24795356; http://dx.doi.org/ 10.1158/2326-6066.CIR-14-0019-T
26. Von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nature reviews 2003; 3:867-78; PMID:14668803; http://dx.doi.org/10.1038/nri1222
27. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer research 2003; 63:12-7; PMID:12517769
28. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59:3340-5; PMID:10416590
29. Huck SP, Tang S-C, Andrew KA, Yang J, Harper JL, Ronchese F. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors. Cancer Immunol Immunother 2008; 57:63-71; PMID:17609951; http:// dx.doi.org/10.1007/s00262-007-0350-z
30. Kupiec-Weglinski JW, Austyn JM, Morris PJ. Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and-independent entry to lymphoid tissues. J Exp Med 1988; 167:632-45; PMID:3258009; http://dx.doi.org/ 10.1084/jem.167.2.632
31. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59:56-8; PMID:9892184
32. Robert C, Klein C, Cheng G, Kogan A, Mulligan RC, von Andrian UH, Kupper TS. Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther 2003; 10:1479-86; PMID:12900763; http://dx.doi. org/10.1038/sj.gt.3302008
33. Scandella E, Fink K, Junt T, Senn BM, Lattmann E, Förster R, Hengartner H, Ludewig B.Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration. J Immunol 2007; 178:1468-76; PMID:17237395; http://dx.doi.org/10.4049/jimmunol.178.3.1468
34. Okada T, Miller MJ, Parker I, Krummel MF, Neighbors M, Hartley SB, O'Garra A, Cahalan MD, Cyster JG. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005; 3:e150; PMID:15857154; http://dx. doi.org/10.1371/journal.pbio.0030150
35. Ekland EH, Forster R, Lipp M, Cyster JG. Requirements for follicular exclusion and competitive elimination of autoantigen-binding B cells. J Immunol 2004; 172:4700-8; PMID:15067045; http://dx.doi.org/ 10.4049/jimmunol.172.8.4700
36. Gunzer M, Schäfer A, Borgmann S, Grabbe S, Zänker KS, Bröcker EB, Kämpgen E, Friedl P. Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity 2000; 13:323-32; PMID:11021530; http:// dx.doi.org/10.1016/S1074-7613(00)00032-7
37. Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood 2007; 109:661-9; PMID:17003381; http://dx. doi.org/10.1182/blood-2005-12-023044
38. Balkow S, Heinz S, Schmidbauer P, Kolanus W, Holzmann B, Grabbe S, Laschinger M. LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming. Blood 2010; 116:1885-94; PMID:20530790; http://dx.doi.org/10.1182/ blood-2009-05-224428
39. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106:263-6; PMID:11509174; http://dx.doi.org/10.1016/S0092-8674(01)00455-X
40. Faroudi M, Zaru R, Paulet P, Müller S, Valitutti S. Cutting edge: T lymphocyte activation by repeated immunological synapse formation and intermittent signaling. J Immunol 2003; 171:1128-32; PMID:12874197; http:// dx.doi.org/10.4049/jimmunol.171.3.1128
41. Matheu MP, Su Y, Greenberg ML, Blanc CA, Parker I, Scott DW, CahalanMD. Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance. Proc Natl Acad Sci USA 2012; 109:E1258-66; PMID:22511718; http://dx.doi.org/10.1073/pnas.1205150109
42. Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM, Schultze JL, von Bergwelt-Baildon MS. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res 2008; 14:6574-9; PMID:18927298; http://dx.doi. org/10.1158/1078-0432.CCR-08-0825
43. Shimabukuro-Vornhagen A, Liebig TM, Koslowsky T, Theurich S, von Bergwelt-Baildon MS. The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect. Cell Immunol 2013; 281:62-7; PMID:23454682; http://dx.doi.org/10.1016/j.cellimm.2013.01.001
44. Von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, Fiore F, Roth U, Beyer M, Debey S, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006; 108:228-37; PMID:16522817; http://dx.doi. org/10.1182/blood-2005-08-3507